Phase II/III Study of Fluorouracil (5-FU) and its Modulation in Advanced Colorectal Cancer

Closed

Phase

Accrual

100%

Published

Abbreviated Title

Phase II/III Study of Fluorouracil (5-FU) and its Modulation in Advanced Colorectal Cancer

Activated

08/01/1989

Closed

01/01/1993

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2005

Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma

K Chansky;J Benedetti;JS Macdonald Cancer 103(6):1165-1171

1995

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study

CG Leichman;TR Fleming;FM Muggia;CM Tangen;B Ardalan;JH Doroshow;FJ Meyers;RF Holcombe;GR Weiss;A Mangalik;JS Macdonald Journal of Clinical Oncology 13(6):1303-1311

1993

Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): A Southwest Oncology Group screening trial.

CG Leichman;TR Fleming;FM Muggia;B Ardalan;J Doroshow;C Tangen;J Macdonald ASCO 12:198(#583)

Selection designs for pilot studies based on survival.

PY Liu;S Dahlberg;J Crowley Biometrics 49:391-398